BRAF and melanoma: The most common immuno- and/or targeted therapies prescribed for the treatment of advanced melanoma in this case series were PD-1 blocker (pembrolizumab, n = 29), BRAF inhibitor (dabrafenib, n = 14) and MEK inhibitor (trametinib n = 14).